ATHE News and Press, Alterity Therapeutics Limited From 04/28/25

MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...

– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS...

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...

– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Al...

2025-02-10 08:54:31 ET More on Alterity Therapeutics Alterity surges after mid-stage trial data for lead asset Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics Financial information for Alterity T...

– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Australia and SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

2025-01-30 08:36:46 ET DENVER, Colo., Jan 30, 2025 ( 247marketnews.com )- Alterity Therapeutics (NASDAQ: ATHE ) reported positive Phase 2 ATH434-201 trial topline results, for patients with early-stage Multiple System Atrophy (MSA). The data highlights clinical and biomarker-based i...

– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain...

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025 ATH434-201 trial in early-stage MSA completed in November 2024 Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in ad...